Literature DB >> 23382084

Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.

Erin H Seeley1, Mary K Washington, Richard M Caprioli, Amosy E M'Koma.   

Abstract

PURPOSE: Although Crohn's colitis (CC) and ulcerative colitis (UC) share several clinical features, they have different causes, mechanisms of tissue damage, and treatment options. Therefore, the accurate diagnosis is of paramount importance in terms of medical care. The distinction between CC/UC is made on the basis of clinical, radiologic, endoscopic, and pathologic interpretations but cannot be differentiated in up to 15% of inflammatory bowel disease patients. Correct management of this "indeterminate colitis" depends on the accuracy of future, and yet not known, destination diagnosis (CC/UC). EXPERIMENTAL
DESIGN: We have developed a proteomic methodology that has the potential to discriminate between UC/CC. The histologic layers of 62 confirmed UC/CC tissues were analyzed using MALDI-MS for proteomic profiling.
RESULTS: A Support Vector Machine algorithm consisting of 25 peaks was able to differentiate spectra from CC and UC with 76.9% spectral accuracy when using a leave-20%-out cross-validation. Application of the model to the entire dataset resulted in accurate classification of 19/26 CC patients and 36/36 UC patients when using a 2/3 correct cutoff. A total of 114 peaks were found to have Wilcoxin rank sum p-values of less than 0.05. CONCLUSION AND CLINICAL RELEVANCE: This information may provide new avenues for the development of novel personalized therapeutic targets.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Colon tissue profiling; Crohn's colitis; Mass spectrometry; Ulcerative colitis

Mesh:

Substances:

Year:  2013        PMID: 23382084      PMCID: PMC3737405          DOI: 10.1002/prca.201200107

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  39 in total

1.  Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease.

Authors:  Howard A Kader; Velizar T Tchernev; Ebenezer Satyaraj; Serguei Lejnine; Gregory Kotler; Stephen F Kingsmore; Dhavalkumar D Patel
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

2.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.

Authors:  F Costa; M G Mumolo; L Ceccarelli; M Bellini; M R Romano; C Sterpi; A Ricchiuti; S Marchi; M Bottai
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Inflammatory bowel disease: an update on the fundamental biology and clinical management.

Authors:  Richard Blumberg; Judy Cho; James Lewis; Gary Wu
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

Review 4.  Pouch-related dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis.

Authors:  J W Um; A E M'Koma
Journal:  Tech Coloproctol       Date:  2011-02-02       Impact factor: 3.781

Review 5.  Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

Authors:  Amosy E M'Koma; Harold L Moses; Samuel E Adunyah
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

6.  Crohn's disease in the ileal pouch after total colectomy for ulcerative colitis: findings on pouch enemas in six patients.

Authors:  Nicolaus A Wagner-Bartak; Marc S Levine; Stephen E Rubesin; Igor Laufer; John L Rombeau; Gary R Lichtenstein
Journal:  AJR Am J Roentgenol       Date:  2005-06       Impact factor: 3.959

7.  Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.

Authors:  D Turner; S T Leach; D Mack; K Uusoue; R McLernon; J Hyams; N Leleiko; T D Walters; W Crandall; J Markowitz; A R Otley; A M Griffiths; A S Day
Journal:  Gut       Date:  2010-09       Impact factor: 23.059

8.  Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.

Authors:  Amosy E M'Koma; Erin H Seeley; Mary K Washington; David A Schwartz; Roberta L Muldoon; Alan J Herline; Paul E Wise; Richard M Caprioli
Journal:  Inflamm Bowel Dis       Date:  2010-08-30       Impact factor: 5.325

9.  Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort.

Authors:  Kelvin T Thia; William J Sandborn; William S Harmsen; Alan R Zinsmeister; Edward V Loftus
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

10.  Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines.

Authors:  Akbar K Waljee; Joel C Joyce; Sijian Wang; Aditi Saxena; Margaret Hart; Ji Zhu; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-14       Impact factor: 11.382

View more
  26 in total

Review 1.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

2.  Mass Spectrometry Imaging Can Distinguish on a Proteomic Level Between Proliferative Nodules Within a Benign Congenital Nevus and Malignant Melanoma.

Authors:  Rossitza Lazova; Zhe Yang; Constantin El Habr; Young Lim; Keith Adam Choate; Erin H Seeley; Richard M Caprioli; Li Yangqun
Journal:  Am J Dermatopathol       Date:  2017-09       Impact factor: 1.533

3.  High Throughput In Situ DDA Analysis of Neuropeptides by Coupling Novel Multiplex Mass Spectrometric Imaging (MSI) with Gas-Phase Fractionation.

Authors:  Chuanzi OuYang; Bingming Chen; Lingjun Li
Journal:  J Am Soc Mass Spectrom       Date:  2015-10-05       Impact factor: 3.109

Review 4.  Systems medicine: evolution of systems biology from bench to bedside.

Authors:  Rui-Sheng Wang; Bradley A Maron; Joseph Loscalzo
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2015-04-17

5.  Gastrointestinal endoscopy biopsy derived proteomic patterns predict indeterminate colitis into ulcerative colitis and Crohn's colitis.

Authors:  Billy Ray Ballard; Amosy Ephreim M'Koma
Journal:  World J Gastrointest Endosc       Date:  2015-06-25

Review 6.  Diagnosis of inflammatory bowel disease: Potential role of molecular biometrics.

Authors:  Amosy E M'Koma
Journal:  World J Gastrointest Surg       Date:  2014-11-27

7.  A recommended and verified procedure for in situ tryptic digestion of formalin-fixed paraffin-embedded tissues for analysis by matrix-assisted laser desorption/ionization imaging mass spectrometry.

Authors:  Audra M Judd; Danielle B Gutierrez; Jessica L Moore; Nathan Heath Patterson; Junhai Yang; Carrie E Romer; Jeremy L Norris; Richard M Caprioli
Journal:  J Mass Spectrom       Date:  2019-08       Impact factor: 1.982

Review 8.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

9.  Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature.

Authors:  Yael Haberman; Timothy L Tickle; Phillip J Dexheimer; Mi-Ok Kim; Dora Tang; Rebekah Karns; Robert N Baldassano; Joshua D Noe; Joel Rosh; James Markowitz; Melvin B Heyman; Anne M Griffiths; Wallace V Crandall; David R Mack; Susan S Baker; Curtis Huttenhower; David J Keljo; Jeffrey S Hyams; Subra Kugathasan; Thomas D Walters; Bruce Aronow; Ramnik J Xavier; Dirk Gevers; Lee A Denson
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

Review 10.  Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.

Authors:  Tue Bennike; Svend Birkelund; Allan Stensballe; Vibeke Andersen
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.